Stimulants

Thozalinone (USAN) (brand name Stimsen; former developmental code name CL-39808) is a psychostimulant that has been used as an antidepressant in Europe. It has also been trialed as an anorectic. Thozalinone is described as a "dopaminergic stimulant", and likely acts via inducing the release of dopamine and to a minimal extent norepinephrine; similar to analogue pemoline, it is reportedly devoid of abuse potential unlike most other dopaminergic psychostimulants.

Etamivan (INN, or ethamivan (USAN); trade names Analepticon, Emivan, and Vandid) is a respiratory stimulant drug related to nikethamide. It was mainly used in the treatment of barbiturate overdose and chronic obstructive pulmonary disease, but has now largely fallen into disuse.

poisonous psychoactive drug

2-Aminotetralin (2-AT), also known as 1,2,3,4-tetrahydronaphthalen-2-amine (THN), is a stimulant drug of the 2-aminotetralin family with a chemical structure consisting of a tetralin core with an amine as substituent.

Octodrine, also known as dimethylhexylamine (DMHA) and sold under the brand name Vaporpac among others, is a sympathomimetic and stimulant medication that was formerly used in the treatment of hypotension (low blood pressure).

Diphenylprolinol (D2PM), or (R/S)-(±)-diphenyl-2-pyrrolidinyl-methanol, is a norepinephrine-dopamine reuptake inhibitor which is used as a designer drug.

CX717 is an ampakine compound created by Christopher Marrs and Gary Rogers in 1996 at Cortex Pharmaceuticals. It affects the neurotransmitter glutamate, with trials showing the drug improves cognitive functioning and memory.

Tametraline (CP-24,441) is the parent of a series of chemical compounds investigated at Pfizer that eventually led to the development of sertraline.

Thiopropamine, also known as 1-(2-thienyl)-2-aminopropane, is a stimulant drug of the arylalkylamine family. It is an analogue of amphetamine where the phenyl ring has been replaced by thiophene. It has similar stimulant effects to amphetamine but with around one third the potency. The N-methyl and thiophen-3-yl analogues are also known and are somewhat more potent, though still generally weaker than the corresponding amphetamines.

1,3-Dimethylbutylamine (1,3-DMBA, dimethylbutylamine, DMBA, 4-amino-2-methylpentane, or AMP), is a stimulant drug structurally related to methylhexanamine where a butyl group replaces the pentyl group. The compound is an aliphatic amine.

recreational drug

Metamfepramone (INN; also known as dimepropion (BAN), dimethylcathinone, and dimethylpropion) is a stimulant drug of the phenethylamine, and cathinone chemical classes. Dimethylcathinone was evaluated as an appetite suppressant and for the treatment of hypotension, but was never widely marketed.

2,5-Dimethoxy-4-nitroamphetamine (DON) is a psychedelic drug of the phenethylamine, amphetamine, and DOx families. Unlike related drugs like DOB, it produces both pronounced hallucinogenic and amphetamine-like stimulant effects. The drug is taken orally.

ABT-418 is a drug developed by Abbott, that has nootropic, neuroprotective and anxiolytic effects, and has been researched for treatment of both Alzheimer's disease and ADHD. It acts as an agonist at neural nicotinic acetylcholine receptors, subtype-selective binding with high affinity to the α4β2, α7/5-HT3, and α2β2 nicotinic acetylcholine receptors but not α3β4 receptors ABT-418 was reasonably effective for both applications and fairly well tolerated, but produced some side effects, principally nausea, and it is unclear whether ABT-418 itself will proceed to clinical development or if anothe

3-Methoxyamphetamine (3-MA), also known as '''meta-methoxyamphetamine (MMA'), is a monoamine releasing agent (MRA) of the amphetamine family. It is a positional isomer of para''-methoxyamphetamine (PMA; 4-methoxyamphetamine). The drug has been encountered as a novel designer drug.

4-Benzylpiperidine is a drug and research chemical used in scientific studies. It has been encountered as a designer drug.

1-Benzyl-4-[2-(diphenylmethoxy)ethyl]piperidine is a stimulant of the piperidine class which acts as a potent and selective dopamine reuptake inhibitor. It is closely related to vanoxerine and GBR-12,935, which in contrast are piperazines.

Cyprodenate (Actebral) is a stimulant drug. It was used for counteracting the effects of benzodiazepine tranquillizer drugs before the development of newer antidotes such as flumazenil. It produces dimethylethanolamine as a metabolite.

(–)-Benzofuranylpropylaminopentane (BPAP; developmental code name FPFS-1169) is an experimental drug related to selegiline which acts as a monoaminergic activity enhancer (MAE). It is orally active in animals.

RTI-126 ('RTI-4229-126 or (–)-2β-(1,2,4-oxadiazol-5-methyl)-3β-phenyltropane') is a phenyltropane derivative which acts as a potent monoamine reuptake inhibitor and stimulant drug, and has been sold as a designer drug. It is around 5 times more potent than cocaine at inhibiting monoamine reuptake in vitro, but is relatively unselective. It binds to all three monoamine transporters, although still with some selectivity for the dopamine transporter. RTI-126 has a fast onset of effects and short duration of action, and its pharmacological profile in animals is among the closest to cocaine itself

Fluminorex is a centrally acting sympathomimetic which is related to other drugs such as aminorex and pemoline. It was developed as an appetite suppressant by McNeil Laboratories in the 1950s. ==Synthesis== class=skin-invert-image|500px|thumb|center|Synthesis: Patent (Ex XV): 2-amino-1-[4-(trifluoromethyl)phenyl]ethanol [776-02-3] (1) cyanogen bromide [506-68-3] (2)

CX-516 is an ampakine and nootropic that acts as an AMPA receptor positive allosteric modulator and had been undergoing development by a collaboration between Cortex, Shire, and Servier. It was studied as a potential treatment for Alzheimer's disease under the brand name Ampalex, and was also being examined as a treatment for ADHD.

6-Bromo-MDA, also known as 6-bromo-3,4-methylenedioxyamphetamine or as 2-bromo-4,5-methylenedioxyamphetamine (2-bromo-4,5-MDA), is a psychoactive drug of the phenethylamine, amphetamine, and MDxx families related to 3,4-methylenedioxyamphetamine (MDA). It is the 6-bromo derivative of MDA. In his book PiHKAL (Phenethylamines I Have Known and Loved), Alexander Shulgin lists 6-bromo-MDA's dose as 350mg orally and its duration as unknown. 6-Bromo-MDA has been reported to produce amphetamine-like effects with no other details provided. However, Daniel Trachsel reported that 6-bromo-MDA was inactive

ephedrine, caffeine, and aspirin

2-Benzylpiperidine is a stimulant drug of the arylpiperidine family. It is similar in structure to certain other stimulants such as methylphenidate and desoxypipradrol. However, it is far less potent as a monoamine reuptake inhibitor in comparison. The drug is little used as a stimulant, with its main use being as a synthetic intermediate in the manufacture of other drugs.

Fenmetramide is a drug which was patented as an antidepressant by McNeil Laboratories in the 1960s. The drug was never marketed. It is the 5-ketone derivative of phenmetrazine and would similarly be expected to produce psychostimulant effects, though pharmacological data is lacking.

cocaine analogue

4-Bromo-2,5-dimethoxy-1-benzylpiperazine (2C-B-BZP) is a psychoactive drug and research chemical of the piperazine chemical class which has been sold as a "designer drug". It produces stimulant effects similar to those of benzylpiperazine (BZP).

Fladrafinil (developmental code name CRL-40,941), also known as fluorafinil or as bisfluoroadrafinil, is a wakefulness-promoting agent related to modafinil that was never marketed. It is sold online and used non-medically as a nootropic (cognitive enhancer).

psychoactive drug

3-Fluoroethamphetamine (3-FEA) is a stimulant drug of the amphetamine class which acts as a releasing agent of the monoamine neurotransmitters norepinephrine, dopamine and serotonin.

5-APB, also known as 5-(2-aminopropyl)benzofuran, is an entactogen of the phenethylamine, amphetamine, and benzofuran families. 5-APB and related drugs have sometimes been informally called "Benzofury".

Benzedrone (4-MBC) is a designer drug which has been found since 2010 as an ingredient in a number of "bath salt" mixes sold as recreational drugs.

PNU-99,194(A) (or U-99,194(A)) is a drug of the 2-aminoindane family which acts as a moderately selective D3 receptor antagonist with ~15-30-fold preference for D3 over the D2 subtype. Though it has substantially greater preference for D3 over D2, the latter receptor does still play some role in its effects, as evidenced by the fact that PNU-99,194 weakly stimulates both prolactin secretion and striatal dopamine synthesis, actions it does not share with the more selective (100-fold) D3 receptor antagonists S-14,297 and GR-103,691.

1-(2-Phenylethyl)pyrrolidine (PEP) is a chemical compound of the phenethylamine family. It is an analogue of 2-phenylethylamine where the amine has been replaced by a pyrrolidine ring.

Isopropylphenidate (also known as IPH and IPPD) is a piperidine based stimulant drug, closely related to methylphenidate, but with the methyl ester replaced by an isopropyl ester. It has similar effects to methylphenidate but with a longer duration of action, and was banned in the UK as a Temporary Class Drug from April 2015 following its unapproved sale as a designer drug.

Ispronicline (TC-1734, AZD-3480) is an experimental drug which acts as a partial agonist at neural nicotinic acetylcholine receptors. It progressed to phase II clinical trials for the treatment of dementia and Alzheimer's disease, but is no longer under development.

'3β-(p-Fluorobenzoyloxy)tropane, (8-Methyl-8-azabicyclo[3.2.1]oct-3-yl 4-fluorobenzoic acid ester, 4-fluorotropacocaine, 3-Pseudotropyl-4-fluorobenzoate, 3-pseudotropyl-4-fluorobenzoate, pFBT') is a tropane derivative drug which acts as a local anaesthetic, having around 30% the stimulant potency of cocaine but around the same potency as a local anaesthetic. It has been investigated as a potential radiolabelled agent for studying receptor binding, but was not adopted for this application. The main application for fluorotropacocaine, however, has been as a designer drug analogue of cocaine, fir

AL-1095, is a centrally acting stimulant drug with comparable effects to amphetamine, developed by Bristol in the 1970s.

Rivanicline (TC-2403, RJR-2403, (E)-metanicotine) is a drug which acts as a partial agonist at neural nicotinic acetylcholine receptors. It is subtype-selective, binding primarily to the α4β2 subtype. It has nootropic effects and was originally developed as a potential treatment for Alzheimer's disease, but a second action that was subsequently found was that it inhibits the production of Interleukin-8 and thus produces an antiinflammatory effect, and so it has also been developed as a potential treatment for ulcerative colitis. Rivanicline also has stimulant and analgesic actions which are th

Clofenciclan (also known as chlorphencyclan; trade names Tonquil and Vesitan) is a dopamine-releasing agent developed by Boehringer & Soehne in the 1950s. It proved unpopular as a treatment because of its pronounced stimulant activity.

Methylbenzylpiperazine (1-methyl-4-benzylpiperazine, MBZP) is a stimulant drug which is a derivative of benzylpiperazine. MBZP has been sold as an ingredient in legal recreational drugs known as "party pills", initially in New Zealand and subsequently in other countries around the world.

Tebanicline (ebanicline, ABT-594) is a potent synthetic nicotinic (non-opioid) analgesic drug developed by Abbott. It was developed as a less toxic analog of the potent poison dart frog-derived compound epibatidine, which is about 200 times stronger than morphine as an analgesic, but produces extremely dangerous toxic side effects. Like epibatidine, tebanicline showed potent analgesic activity against neuropathic pain in both animal and human trials, but with far less toxicity than its parent compound. It acts as a partial agonist at neuronal nicotinic acetylcholine receptors, binding to both

Hexacyclonate (Gevilon) is a stimulant drug. It has been used for the treatment of alcoholism and for increasing motivation in elderly patients, but Gevilon (containing a different active substance - gemfibrozil) is now mainly used for the treatment of hyperlipoproteinaemia. It is chemically similar to the anticonvulsant gabapentin, with a hydroxyl group replacing the amine.

1-Phenyl-2-propylaminopentane (PPAP), also known as 'α,N-dipropylphenethylamine (DPPEA) and by the developmental code name MK-306', is an experimental drug related to selegiline which acts as a catecholaminergic activity enhancer (CAE).

Difluoropine (O-620) is a stimulant drug synthesised from tropinone, which acts as a potent and selective dopamine reuptake inhibitor. Difluoropine is unique among the tropane-derived dopamine reuptake inhibitors in that the active stereoisomer is the (S) enantiomer rather than the (R) enantiomer, the opposite way round compared to natural cocaine. It is structurally related to benztropine and has similar anticholinergic and antihistamine effects in addition to its dopamine reuptake inhibitory action.

Epiboxidine is a chemical compound which acts as a partial agonist at neural nicotinic acetylcholine receptors, binding to both the α3β4 and the α4β2 subtypes. It was developed as a less toxic analogue of the potent frog-derived alkaloid epibatidine, which is around 200 times stronger than morphine as an analgesic but is deadly toxic.

Isopropylamphetamine is a psychostimulant of the substituted amphetamine class. It is an isomer of propylamphetamine and was discovered by a team at Astra Läkemedel AB. The isopropyl moiety reduces the stimulant activity of the compound but greatly increases the duration of action. For this reason, the compound is not used recreationally.

SKF-38393 is a synthetic compound of the 3-benzazepine family which acts as a selective dopamine D1 and D5 receptor partial agonist. It has stimulant and anorectic effects.

Indanorex, sold under the brand name Dietor, is a stimulant drug which was developed in the 1970s. It has appetite suppressant effects and also has antihypoglycemia effects. A chemical synthesis has been reported.

2-Amino-1,2-dihydronapthalene (2-ADN or ADN) is a stimulant drug. It is a rigid analogue of phenylisobutylamine and substitutes for amphetamine in rat drug discrimination tests, although at approximately one-fourth the potency.

ABT-202 is a drug developed by Abbott, which acts as an agonist at neural nicotinic acetylcholine receptors and has been researched for use as an analgesic, although it has not passed clinical trials.

Benocyclidine, also known as benzothiophenylcyclohexylpiperidine (BTCP), is a psychoactive recreational drug of the arylcyclohexylamine class which is related to phencyclidine (PCP). It was first described in a patent application naming Marc Caron and colleagues at Duke University in 1997.

UH-232 ((+)-UH232) is a drug which acts as a subtype selective mixed agonist-antagonist for dopamine receptors, acting as a weak partial agonist at the D3 subtype, and an antagonist at D2Sh autoreceptors on dopaminergic nerve terminals. It causes dopamine release in the brain and has a stimulant effect, as well as blocking the behavioural effects of cocaine. It may also serve as a 5-HT2A receptor agonist, based on animal studies. It was investigated in clinical trials for the treatment of schizophrenia, but unexpectedly caused symptoms to become worse.

AR-R17779 is a drug that acts as a potent and selective full agonist for the α7 subtype of neural nicotinic acetylcholine receptors. It has nootropic effects in animal studies, but its effects do not substitute for those of nicotine. It has also been studied as a potential novel treatment for arthritis.

Cilobamine is a drug which acts as a norepinephrine-dopamine reuptake inhibitor (NDRI) and has stimulant and antidepressant effects.

3,4-dichloromethylphenidate (abbreviated as 3,4-DCMP, and incorrectly as 3,4-CTMP for the d,l-threo diastereomer) is a potent stimulant drug from the phenidate class closely related to methylphenidate. It acts as a potent serotonin-norepinephrine-dopamine reuptake inhibitor with a long duration of action. It has been sold online as a designer drug.

SCH-5472. is a stimulant drug developed by Schering-Plough in the 1950s.

Camfetamine (N-methyl-3-phenyl-norbornan-2-amine) is a stimulant drug closely related to the appetite suppressant fencamfamine, being its N-methyl homologue. It has been sold as a designer drug following the banning of mephedrone and related substituted cathinone derivatives in many countries, and reportedly has slightly stronger stimulant effects than fencamfamine, but with correspondingly more severe side effects.

'''4'-Methyl-α-pyrrolidinobutiophenone or MPBP''' is a stimulant compound which has been reported as a novel designer drug. It is closely related to pyrovalerone, being simply its chain-shortened homologue.